Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes

Neurodegener Dis Manag. 2023 Apr;13(2):75-84. doi: 10.2217/nmt-2022-0038. Epub 2022 Dec 23.

Abstract

Aim: Evaluate timing of motor improvement with carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO) in patients with Parkinson's disease and OFF episodes. Methods: A post hoc pooled analysis from two studies assessed Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) scores and investigator-rated FULL ON. Results: At 15 and 30 min following the prescribed first daily CD/LD dose, mean improvements in MDS-UPDRS-III scores were -6.7 and -16.3, respectively, and FULL ON was achieved by 6.5 and 41.8% of patients. Following an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7 and 81.0% of patients. Conclusion: Concomitant administration of SL-APO with carbidopa/levodopa may be useful for delayed ON.

Keywords: Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III; OFF episodes; Parkinson's disease; apomorphine sublingual film; carbidopa/levodopa; delayed ON; morning OFF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiparkinson Agents / therapeutic use
  • Apomorphine
  • Carbidopa / therapeutic use
  • Drug Combinations
  • Humans
  • Levodopa* / therapeutic use
  • Parkinson Disease* / drug therapy

Substances

  • Levodopa
  • Carbidopa
  • Apomorphine
  • Antiparkinson Agents
  • Drug Combinations